Zhengye Biotechnology Holding Limited (ZYBT)
Healthcare
- Fundamental
- 1
- Sentiment
- 3
- Technical
- 3
Do Nothing: fundamentalScore is 1 (below required floor of 3); additionally, max overnight gap is 68.21% and recent 3-session regular-session dollar volume averages only $1,614.42, so the tape is untradeable for this strategy.
Company overview
Zhengye Biotechnology Holding Limited develops and markets vaccines for animal health, focusing on the Chinese agricultural sector. The company's products cater to a variety of farm animals and are also exported to countries like Vietnam, Pakistan, and Egypt. Established in 2004, it operates as a subsidiary of Securingium Holding Limited, with its main operations in Jilin, China.
Fundamental
very weakThe company faces severe operational deterioration and regulatory risks, making it too risky for investment.
Too risky: FY2025 revenue fell 37.56% and profitability swung to a deep loss (net margin -59.97%, EBITDA margin -36.54%). SEC filings highlight PRC regulatory/controls risks plus a Nasdaq $1 minimum bid-price deficiency notice (deadline 2026-11-25). With an extremely low free float (~9%) and discounted-cash-flow outputs far below the current price, the risk/reward is unfavorable.
Sentiment
fairRetail interest is high, but unresolved compliance issues and lack of media coverage create conflicting sentiment signals.
ZYBT’s near-term action looks driven by a same-day retail/momentum burst (Reddit posts flagging extreme RVOL and large % moves; confidence: rumored) while mainstream news flow in the last ~14 days is effectively absent, making the sentiment delta indeterminate. The unresolved Nasdaq minimum-bid-price deficiency (announced 2026-06-04) adds a bearish overhang that conflicts with the bullish tape, so the setup is capped at 3 on the Red-Flag Screen (mixed/conflicting signals + promotional chatter).
Technical
fairRecent price surge indicates a high-volatility breakout driven by retail momentum rather than stable fundamentals.
Price exploded above SMA20/50/200 and EMA9/21 with MACD turning strongly positive and ADX14 at 31.99, but RSI14 93.34 and Williams %R -3.15 show a severely stretched one-day squeeze rather than a stable low-risk continuation base.
You’re looking at 2026-07-20 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.